IOPen underestimates IOP measurements

Article

The IOPen rebound tonometer underestimates intraocular pressure (IOP) measurements compared to Goldmann applanation tonometer (GAT) and ocular response analyzer (ORA).

The IOPen rebound tonometer underestimates intraocular pressure (IOP) measurements compared to Goldmann applanation tonometer (GAT) and ocular response analyzer (ORA), reveals a study published in Eye.

Dr J. Moreno-Montañés et al., Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain, conducted a cross-sectional, randomized study on 198 normal eyes. The Bland and Altman limits of agreement (LoA) were used to calculate agreement between all three tonometers.The median IOPen IOP was 3 mm Hg below the GAT and the ORA IOP. LoA width between the IOPs of the IOPen and the GAT ranged between 13.92 and 15.99 mm Hg. Central corneal thickness (CCT) was not linked to the IOPen measurements, but corneal hysteresis (CH) and corneal rigidity factor (CRF) were linked to measurements by IOPen and GAT.

IOPen underestimated the IOP compared with GAT and ORA. The effect of measurement quality or measurement order on IOPen was low. CCT did not affect the IOPen, but the CH and CRF did. The LoA width between the IOPen and GAT IOPs was higher than between the ORA IOPg or ORA IOPcc and GAT IOPs.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.